The neglected tropical diseases diagnosis market size is estimated to be USD 6,178.2 million in 2022 and is expected to witness a CAGR of 4.71% during the forecast period 2023-2033. Increasing public awareness of NTDs and rise in government activities are factors contributing to the market growth. Additionally, rising prevalence of the disease, growing adoption for early disease identification, and complementary technological improvements is expected to support the market growth. However, is expected to hinder the growth.

Rising prevalence of the disease is expected to fuel the market growth. More than 1.7 billion people, or nearly one-fifth of the world’s population, mostly living in developing and low-income nations, required interventions for at least one NTD each year, according to WHO estimates. NTDs impacted over 40% of the African continent. The poor population inhabiting tropical regions and difficult-to-access locations is more likely to get these diseases. The majority of NTD cases worldwide are generated by countries including Brazil, Yemen, India, Bangladesh, China, and several countries in Central & East Africa.

Increasing public awareness of NTDs is predicted to fuel the market growth. The Global NTD Program by the Centers for Disease Control and Prevention, Global NTD Programs by the World Health Organization, NTD Program by the United States Agency for International Development, and the United States Global Health Initiative are just a few of the organisations that have launched numerous programmes to raise awareness of NTDs globally. All of these initiatives are primarily concerned with limiting or getting rid of NTDs. Similar to this, the London Declaration was formed to continue, develop, and extend various programmes to support & manage trachoma, schistosomiasis, sleeping sickness, lymphatic filariasis, leprosy, and Chagas disease by 2020.

Segmentation

By Disease

The market is categorized into rabies, soil-transmitted helminth infections, dengue, leprosy, yaws, echinococcosis, dracunculiasis, onchocerciasis, snakebite envenoming, buruli ulcer, and leishmaniasis. In the global market, the soil-transmitted helminth infections segment accounted for the largest revenue share in 2022 owing to the rising incidence and widespread use of diagnostic testing. Furthermore, molecular diagnostics have a benefit over conventional and quick testing due to their low false-positive rate. More than 1.5 billion people globally are expected to have soil-transmitted helminth infections as of January 2022, according to the WHO. The segment for dracunculiasis is anticipated to grow at the fastest rate, over the forecast period. With 27 human cases reported in 2020, it is a severe parasite infection that is almost completely eradicated. 12 human cases of the disease reported in Chad in 2020, down from 48 in 2019. There have been 11 reported cases of this in Ethiopia, and one each in Angola, Cameroon South, Sudan, and Mali. The expansion of the disease, rising public awareness, greater test prices, and other factors play a role in the segment’s revenue expansion.

By Diagnostic Method

The market is divided into molecular/modern method and conventional method. In 2022, the molecular/modern method segment accounted for the highest revenue share due to high usage rates. The market is anticipated to grow due to surge in R&D for molecular diagnostic techniques and an increasing demand for point-of-care solutions. Specificity, sensitivity, cost-effectiveness, and the availability of experienced individuals are all factors taken into account while selecting between different diagnostic procedures. Conventional diagnostic techniques rely on gram stain, pathogen culture, biochemical procedures, and serology testing for microscopic and macroscopic detection of pathogens. The fact that conventional methods are more widely available than modern techniques across many labs and clinics is a crucial factor in this segment’s growth in the market.  Additionally, rapid technical advancements are pushing end users to choose molecular/modern approaches over conventional models.

By Service Type

The market is segregated into POC service and centralised service. In the global market, the centralised service segment accounted for the largest revenue share in 2022 owing to high volume of procedures and the widespread presence of ancillary support in terms of infrastructure and human resources. The PoC segment is going to grow the fastest during the predicted period. One of the main reasons driving the segment growth is the growing need for bedside patient care due to the expanding home healthcare market, technological improvements, and rising market penetration. POC services also offer fast outcomes, enabling quick diagnosis and better patient outcomes. Additionally, the first POC test, “Chagas Detect Plus Rapid Test Kit,” received a 510K clearance from the U.S. FDA in 2017. InBios International developed this POCT for Chagas disease. Such accomplishments are projected to have a beneficial impact on this segment’s growth over the course of the projection year.

By End Use

The market is segmented into hospitals/clinics, clinical labs, and home healthcare. In 2022, the clinical labs segment accounted for the largest revenue share owing to strong market penetration, high procedure volumes, and a significant number of laboratories in developing and emerging regions. Another significant factor projected to propel the market is a rise in the number of efforts done by the government to provide various services, including such reimbursement for diagnostic tests. However, he home healthcare market is anticipated to expand at the quickest rate as point of care testing services are being frequently used. The hospitals and clinics segment had the second-largest market share. In order to do high-quality testing for NTDs and related antibiotic resistance, public health laboratories play a crucial role. Additionally, the rising cost of healthcare and the burden of disease may spur segment expansion. Additionally, early treatment and testing by hospitals and clinics can help achieve the WHO criteria for the management and eradication of diseases

Regional Markets

In 2022, North America region accounted for the highest revenue in the neglected tropical diseases diagnosis market and is expected to maintain its dominance during the forecast period. This is attributed to the high prevalence of NTDs, rising healthcare costs, quick technology development, pro-active government measures, and growing public awareness of the use of PCR testing in the diagnosis of NTDs. Latin America is predicted to exhibit the quickest CAGR during the forecast period. Rise in multinational diagnostic companies’ focus on the development of innovative & new IVD products, increase in government investment, presence of qualified healthcare professionals, and other factors are projected to propel market expansion in Latin America.

Competitor Insights

Some of the key players operating in the neglected tropical diseases diagnosis market are Coris BioConcept, DiaSys Diagnostic Systems GmbH, Genome Diagnostics Pvt. Ltd., Abbott, Thermo Fisher Scientific Inc., InBios International, Inc., Omega Diagnostics Group PLC, F. Hoffmann-La Roche Ltd, ZeptoMetrix, and Oscar Medicare Pvt Ltd.

To achieve a competitive edge, these businesses are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

• For instance, EUROIMMUN introduced the EUROPatternTM Microscope Live (EPML) compact immunofluorescence microscope in March 2021. This instrument is intended to detect antibodies in the sample and improve indirect immunofluorescence testing.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including disease, diagnostic method, service type, and end use from 2023 to 2033.

Report Scope:

Segmentation: Neglected Tropical Diseases Diagnosis Market Report 2022 – 2033

Disease (Revenue, USD Million), 2022 – 2033

• Rabies
• Soil-transmitted Helminth Infections
• Dengue
• Leprosy
• Yaws
• Echinococcosis
• Dracunculiasis
• Onchocerciasis
• Snakebite Envenoming
• Buruli Ulcer
• Leishmaniasis

Diagnostic Method (Revenue, USD Million), 2022 – 2033

• Molecular/Modern Method
• Conventional Method

Service Type (Revenue, USD Million), 2022 – 2033

• POC Service
• Centralised Service

End Use (Revenue, USD Million), 2022 – 2033

• Hospitals/Clinics
• Clinical Labs
• Home Healthcare

By Region (Revenue, USD Million), 2022 – 2033

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • Rest of MEA